ArticlePLoS pathogens2018
Genetic mechanisms of Coxiella burnetii lipopolysaccharide phase variation.
Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 81 citations in OpenAlex.
- Article
- What goes around comes around: updates in the study ofInfection and immunity · 2026Review
- Stepwise assembly of virulence-associated traits in the intracellular pathogenbioRxiv : the preprint server for biology · 2026Article
- Early detection ofMicrobiology spectrum · 2026Article
- Pardon the interruption: how Und-P sequestration has reshaped our understanding of the bacterial cell envelope.Journal of bacteriology · 2026Review
- Article
- Sources and culture methods for the isolation and cultivation ofFrontiers in microbiology · 2026Review
- Control of human Q fever by vaccination: the journey to Q-VAX and beyond.Infection and immunity · 2025Review
- Review
- Comparison of in-house immunofluorescence assay (IFA) and commercial enzyme-linked immunosorbent assay (ELISA) for Coxiella burnetii infection in cattle.Veterinary research communications · 2025Article
- Q Fever: Who Is at Risk? A Serological Survey in the General Population and Occupationally Exposed Individuals in Northern Italy.Pathogens (Basel, Switzerland) · 2025Article
- A Comparison of Tests for Detecting Prior Exposure toVaccines · 2025Article
- Coxiella burnetii as a model system for understanding host immune response against obligate intracellular, vacuolar pathogens.PLoS pathogens · 2025Article
- Whole genome sequence ofMicrobiology resource announcements · 2025Article
- CRISPR-Cas9-based approaches for genetic analysis and epistatic interaction studies inmSphere · 2024Article
- Navigating Q fever: Current perspectives and challenges in outbreak preparedness.Open veterinary journal · 2024Review
- A Simple and Rapid Microscale Method for Isolating Bacterial Lipopolysaccharides.International journal of molecular sciences · 2024Article
- Natural reversion promotes LPS elongation in an attenuated Coxiella burnetii strain.Nature communications · 2024Article
- Vaccine development: obligate intracellular bacteria new tools, old pathogens: the current state of vaccines against obligate intracellular bacteria.Frontiers in cellular and infection microbiology · 2024Review
- Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Coxiella burnetii is an intracellular pathogen that causes human Q fever, a disease that normally presents as a severe flu-like illness. Due to high infectivity and disease severity, the pathogen is considered a risk group 3 organism. Full-length lipopolysaccharide (LPS) is required for full virulence and disease by C. burnetii and is the only virulence factor currently defined by infection of an immunocompetent animal. Transition of virulent phase I bacteria with smooth LPS, to avirulent phase II bacteria with rough LPS, occurs during in vitro passage. Semi-rough intermediate forms are also observed. Here, the genetic basis of LPS phase conversion was investigated to obtain a more complete understanding of C. burnetii pathogenesis. Whole genome sequencing of strains producing intermediate and/or phase II LPS identified several common mutations in predicted LPS biosynthesis genes. After passage in broth culture for 30 weeks, phase I strains from different genomic groups exhibited similar phase transition kinetics and elevation of mutations in LPS biosynthesis genes. Targeted mutagenesis and genetic complementation using a new C. burnetii nutritional selection system based on lysine auxotrophy confirmed that six of the mutated genes were necessary for production of phase I LPS. Disruption of two of these genes in a C. burnetii phase I strain resulted in production of phase II LPS, suggesting inhibition of the encoded enzymes could represent a new therapeutic strategy for treatment of Q fever. Additionally, targeted mutagenesis of genes encoding LPS biosynthesis enzymes can now be used to construct new phase II strains from different genomic groups for use in pathogen-host studies at a risk group 2 level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.